| Literature DB >> 30417892 |
Raïko Blondonnet1, Bertille Paquette2, Damien Richard3, Rémi Bourg4, Géraldine Laplace4, Romain Segurel4, Henria Pouvelle4, Corinne Belville5, Loic Blanchon5, Thomas Godet2, Jean-Michel Constantin2, Jean-Etienne Bazin2, Vincent Sapin5, Matthieu Jabaudon2.
Abstract
Acute respiratory distress syndrome (ARDS) is a syndrome of diffuse alveolar injury with impaired alveolar fluid clearance and severe inflammation. The use of halogenated agents, such as sevoflurane or isoflurane, for the sedation of intensive care unit (ICU) patients can improve gas exchange, reduce alveolar edema, and attenuate inflammation during ARDS. However, data on the use of inhaled agents for continuous sedation in the ICU to treat or prevent lung damage is lacking. To study the effects of halogenated agents on alveolar epithelial cells under "physiologic" conditions, we describe an easy system to culture cells at the air-liquid interface and expose them to halogenated agents to provide precise controlled "air" fractions and "medium" concentrations for these agents. We developed a sealed air-tight chamber in which plates with human alveolar epithelial immortalized cells could be exposed to a precise, controlled fraction of sevoflurane or isoflurane using a continuous gas flow provided by an anesthetic machine circuit. Cells were exposed to 4% of sevoflurane and 1% of isoflurane for 24 hours. Gas mass spectrometry was performed to determine the concentration of halogenated agents dissolved in the medium. After the first hour, the concentrations of sevoflurane and isoflurane in the medium were 251 mg/L and 25 mg/L, respectively. The curves representing the concentrations of both sevoflurane and isoflurane dissolved in the medium showed similar courses over time, with a plateau reached at one hour after exposure. This protocol was specifically designed to reach precise and controlled concentrations of sevoflurane or isoflurane in vitro to improve our understanding of mechanisms involved in epithelial lung injury during ARDS and to test novel therapies for the syndrome.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30417892 PMCID: PMC6235595 DOI: 10.3791/58554
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355